Larimar Therapeutics opened lower at $2.70, compared with its previous close of $2.73. In the last trading session, the stock traded between $2.51 and $2.76. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Larimar Therapeutics is now worth
$ 21.56
Resulting in a loss of
$ 78.44 (78.44%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.04 (-1.28%)
Day High
$2.76
Day Low
$2.51
Day Open
$2.70
Prev Close
$2.73
Volume
9,24,942
1W Return
-2.88%
1M Return
6.35%
3M Return
-37.40%
6M Return
-34.11%
1Y Return
-25.76%
Market Cap ($ Mn)
280
PE Ratio
-
PB Ratio
3.26
PEG Ratio
-
ROE
-126.84%
ROCE
-123.54%
EPS (TTM)
$-0.32
1 Week
-2.88%
1 Month
6.35%
3 Months
-37.40%
6 Months
-34.11%
9 Months
-19.31%
Larimar completes BLA submission for Friedreich’s ataxia therapy
Larimar completed rolling BLA submission to FDA for nomlabofusp. Seeks accelerated approval for Friedreich’s ataxia treatment. FDA aligned on skin frataxin as potential novel surrogate endpoint. Open-label data showed sustained increases in skin frataxin levels. Global confirmatory Phase 3 study FORWARD-FA currently enrolling.
3 days agoLarimar Therapeutics appoints John Harlow as president and COO
John Harlow appointed President and COO effective September 29, 2026. Role focused on scaling organization for nomlabofusp launch. Inducement grant includes options for 800,000 shares and RSUs for 50,000 shares. Harlow brings 25+ years of commercial experience from Esperion and Melinta.
1mo agoLarimar Therapeutics Q2 Results: EPS beats estimates, losses narrow YoY
Larimar Therapeutics reported Q2 EPS of $(0.30), beating the $(0.39) consensus by 23.08%. Losses narrowed 26.83% YoY from $(0.41), indicating improved financial execution despite remaining in a net loss position.
3mo agoPomerantz investigates Larimar Therapeutics over securities fraud claims
Pomerantz LLP is investigating Larimar Therapeutics, Inc. regarding potential securities fraud after stock price declines linked to clinical trial safety data. The investigation follows announcements in September 2025 and June 2026 revealing anaphylaxis cases in patients treated with nomlabofusp. Investors are advised to contact Danielle Peyton at Pomerantz LLP for information regarding the class action.
4mo agoHC Wainwright assumes Larimar Therapeutics at Buy, target $10
HC Wainwright & Co. analyst Raghuram Selvaraju assumed coverage of Larimar Therapeutics with a Buy rating and set a price target of $10.
4mo agoBaird maintains Outperform on Larimar, lowers target to $5
Larimar Therapeutics submitted the first module of its rolling BLA to the FDA for accelerated approval of nomlabofusp for Friedreich’s ataxia, with remaining modules due in the second half of 2026. The FDA confirmed its willingness to consider FXN as a novel surrogate endpoint. Following this, Baird analyst Joel Beatty maintained an Outperform rating on the stock but reduced the price target from $7 to $5.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Larimar Therapeutics is now worth
$ 21.56
Resulting in a loss of
$ 78.44 (78.44%)
Note: Past profits do not guarantee future returns.
